Rimegepant is a one of the first anti-migraine drugs that target and inhibits the CGRP receptor, a key player in migraines. It has been approved to not only treat acture migraine headache, but also to prevent it from happening. Its unique oral mode of delivery, swift action (using Zydis ODT technology; to learn more about ODT technology in general, click here), and well-tolerated profile position Rimegepant well in a growing market. We provide the essential Rimegepant intermediates to expedite and streamline your drug development process, thus enabling quicker, cost-effective progression to the markets.

This Rimegepant intermediate, CAS No. 1373116-04-1, is derived from CAS No. 1190363-46-2. The protection group is further processed to form one of the last Rimgepant intermediates that reacts with CAS No. 1373116-06-3 to form the Rimegepant API.

References

1. 李泽标, 黄虎, 夏豪, 祁晓庆 & 林燕峰. 一种瑞美吉泮的合成方法. (2023).

2. Luo, G. et al. Asymmetric Synthesis of the Major Metabolite of a Calcitonin Gene-Related Peptide Receptor Antagonist and Mechanism of Epoxide Hydrogenolysis. J. Org. Chem. 82, 3710–3720 (2017).

3. Luo, G. et al. Calcitonin gene-related peptide (CGRP) receptor antagonists: Pyridine as a replacement for a core amide group. Bioorganic & Medicinal Chemistry Letters 22, 2917–2921 (2012).

4. Luo, G. CGRP Receptor Antagonists. (2009).

5. Luo, G., Dubowchik, G. M. & Macor, J. E. Cgrp receptor antagonists. (2011).

6. Leahy, D. K. et al. Process for the preparation of cycloheptapyridine cgrp receptor antagonists. (2012).

7. 阮诗文, 严恭超, 张薇 & 阮晓娜. Rimegepant及其中间体的合成方法. (2022).

8. Trinius, F. Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern. (2014).